arrow
A

Antonio Cuneo

University of Ferrara
H指数:58
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploring the synergy between telomere length and genomic complexity in CLL

探索端粒长度与基因组复杂性在CLL中的协同作用

2026-01-230
OAAI
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort

基于维奈克拉茨方案的八旬慢性淋巴细胞白血病患者:疗效、安全性及与BTKi的比较(多中心队列研究)

2025-04-240
OA
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience
2024-07-151
OAAI
Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis
2024-07-010
PRE
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML
2024-06-040
OAAI
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
CANCER
IF5.1
2023-12-284
OAAI
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CLL历史上的其他恶性肿瘤: ERIC进行的一项国际多中心研究,欧洲CLL研究倡议,和谐

2023-11-016
OAAI
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

慢性淋巴细胞白血病患者新型冠状病毒肺炎和COVID后病情的演变: 欧洲CLL研究计划ERIC的一项研究

2023-09-2911
OAAI
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study

患者对慢性淋巴细胞白血病治疗的偏好: 选择研究

2023-09-296
OA
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study
2023-07-012
OA
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study
2023-06-292
OA
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
2023-05-030
OAAI
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
CANCER
IF5.1
2023-03-1821
OAAI
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
LEUKEMIA
IF13.4
2023-02-1813
OAAI
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518-VERITAS study
2023-01-125
OAAI